StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
5321
This month
104
This week
27
This year
468
Today
12
Yesterday
22
Publishing Date
2024 - 04 - 24
12
Sector
Health technology
11
Manufacturing
1
Tags
Agreement
8
Asco
18
Biopharma
6
Business
10
Cancer
4
Cell
5
Ceo
5
Collaboration
4
Commercial
4
Communications
4
Company
9
Conference
39
Corporation
26
Day
7
Development
10
Disease
5
Drug
5
Earnings
10
Energy
10
Fda
7
Financial
76
First
154
For
97
Gas
4
Global
10
Group
17
Growth
9
International
4
Life
4
Market
23
Medical
5
Meeting
35
Microcap
4
Million
13
Mobile
4
N/a
494
Nasdaq
9
Offering
7
One
5
Partnership
8
Pharmaceuticals
9
Positive
12
Presentation
19
Program
6
Reach
12
Report
50
Research
11
Results
144
Sales
10
Service
5
Solutions
7
Study
13
Technology
8
Therapeutics
27
Topline
5
Treatment
12
Trial
9
Update
12
Water
5
Year
17
Entities
Akebia therapeutics, inc.
1
Alkermes plc
1
Amneal pharmaceuticals, inc.
1
Arrowhead pharmaceuticals, inc.
1
Ascendis pharma a/s
1
Atai life sciences n.v.
1
Hookipa pharma inc.
1
Innoviva, inc.
1
La jolla pharmaceutical company
1
Novartis ag
1
Precigen, inc.
1
Regeneron pharmaceuticals, inc.
1
Sanofi
1
Travere therapeutics inc.
2
Symbols
AKBA
1
ALKS
1
AMRX
1
ARWR
1
ASND
1
ATAI
1
HOOK
1
INVA
1
LJPC
1
NVS
1
NVSEF
1
PGEN
1
REGN
1
SNY
1
SNYNF
1
TVTX
2
Exchanges
Nasdaq
11
Nyse
2
Crawled Date
2024 - 04 - 24
12
Crawled Time
05:00
1
07:00
1
11:00
4
12:00
1
13:00
1
14:00
3
19:00
1
Source
www.biospace.com
4
www.globenewswire.com
6
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
published :
Today
tags :
Treatment
save search
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published:
2024-04-24
(Crawled : 05:00)
- globenewswire.com
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
-0.52%
|
O:
-0.36%
H:
0.05%
C:
-0.15%
malaria
positive
treatment
for
novartis
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published:
2024-04-24
(Crawled : 07:00)
- prnewswire.com
AKBA
|
$1.36
-0.73%
-0.74%
1.5M
|
Health Technology
|
0.0%
|
O:
0.0%
H:
2.19%
C:
0.0%
TVTX
|
$5.46
-4.88%
-5.13%
2M
|
Health Technology
|
-7.78%
|
O:
-2.2%
H:
0.0%
C:
-5.71%
filspari
nephropathy
treatment
for
therapeutics
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published:
2024-04-24
(Crawled : 11:00)
- globenewswire.com
TVTX
|
$5.46
-4.88%
-5.13%
2M
|
Health Technology
|
-7.78%
|
O:
-2.2%
H:
0.0%
C:
-5.71%
filspari
nephropathy
treatment
for
therapeutics
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
Published:
2024-04-24
(Crawled : 11:00)
- globenewswire.com
HOOK
|
$0.843
10.2%
9.25%
10M
|
Health Technology
|
15.02%
|
O:
10.96%
H:
6.1%
C:
3.66%
hb-700
fda
pharma
drug
treatment
clearance
for
application
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published:
2024-04-24
(Crawled : 12:00)
- biospace.com/
INVA
|
$15.15
-0.13%
-0.13%
420K
|
Health Technology
|
0.9%
|
O:
1.03%
H:
0.72%
C:
-0.13%
positive
treatment
global
for
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Published:
2024-04-24
(Crawled : 11:00)
- prnewswire.com
ALKS
|
$24.66
1.65%
1.62%
1.7M
|
Health Technology
|
2.05%
|
O:
0.43%
H:
2.27%
C:
1.61%
narcolepsy
treatment
for
study
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
Published:
2024-04-24
(Crawled : 11:00)
- globenewswire.com
ATAI
|
$1.875
-4.82%
-5.07%
830K
|
Manufacturing
|
-5.56%
|
O:
-1.01%
H:
0.0%
C:
-4.59%
bpl-003
first
life
depression
treatment
sciences
study
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Published:
2024-04-24
(Crawled : 14:00)
- biospace.com/
ARWR
|
$23.285
-2.08%
-2.13%
810K
|
Health Technology
|
-2.06%
|
O:
-0.17%
H:
0.08%
C:
-1.9%
disease
kidney
treatment
pharmaceuticals
for
study
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Published:
2024-04-24
(Crawled : 14:00)
- biospace.com/
AMRX
|
$6.07
12.41%
11.04%
3.1M
|
Health Technology
|
12.04%
|
O:
6.67%
H:
6.08%
C:
5.03%
fda
opioid
approval
treatment
for
spray
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Published:
2024-04-24
(Crawled : 14:00)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-0.27%
|
O:
0.8%
H:
0.0%
C:
-1.05%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
0.82%
|
O:
0.82%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
-0.09%
|
O:
-0.05%
H:
0.97%
C:
-0.04%
asco
tumors
treatment
blood
for
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
Published:
2024-04-24
(Crawled : 13:00)
- globenewswire.com
ASND
|
$143.14
-1.17%
-1.18%
230K
|
Health Technology
|
-1.14%
|
O:
-0.57%
H:
1.67%
C:
-0.57%
yorvipath
treatment
for
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Published:
2024-04-24
(Crawled : 19:00)
- biospace.com/
PGEN
|
$1.42
1.43%
1.41%
560K
|
Health Technology
|
1.43%
|
O:
0.0%
H:
2.14%
C:
1.43%
prgn-2012
respiratory
asco
treatment
immunotherapy
for
meeting
study
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.